Translational Development Acquisition (TDACW) Liabilities and Shareholders Equity (2023 - 2026)

Translational Development Acquisition (TDACW) has reported Liabilities and Shareholders Equity for 4 consecutive years, with $157.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Liabilities and Shareholders Equity fell 11.68% year-over-year to $157.4 million; the trailing twelve-month figure through Jun 2026 stood at $702.4 million (up 32.58% YoY), and the FY2025 full-year result was $181.7 million, up 3.83% from the prior year.
• Liabilities and Shareholders Equity fell to $157.4 million in Q2 2026 per TDACW's latest filing, from $183.3 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $183.3 million in Q1 2026 and bottomed at $2021.0 in Q4 2023.
• Historically, Liabilities and Shareholders Equity has averaged $154.0 million across 4 years, with a median of $177.4 million in 2025.
• The sharpest annual moves came in 2024 and 2026: Liabilities and Shareholders Equity jumped 8659008.31% in 2024, then slipped 11.68% in 2026.
• Over 4 years, Liabilities and Shareholders Equity stood at $2021.0 in 2023, then surged by 8659008.31% to $175.0 million in 2024, then advanced by 3.83% to $181.7 million in 2025, then slipped by 13.39% to $157.4 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $157.4 million, $183.3 million, and $181.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.